Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 7/20 | 0.44 |
| ▸ | AGTR2 | P50052 | 7/20 | 0.44 |
| ▸ | AGT | P01019 | 2/20 | 0.39 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.34 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.34 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7301888 | 0.86 | AGTR1 (0.48) | AGTR1AGTR2AGTABCC3ABCC4 | |
| SCHEMBL7308714 | 0.81 | AGT (0.47) | AGTR1AGTR2AGTABCC3ABCC4 | |
| SCHEMBL7303806 | 0.80 | AGTR1 (0.44) | AGTR1AGTR2AGTABCC3ABCC4 | |
| SCHEMBL8845361 | 0.79 | AGTR1 (0.43) | AGTR1AGTR2AGTABCC3ABCC4 | |
| SCHEMBL8845233 | 0.76 | AGTR1 (0.47) | AGTR1AGTR2AGT | |
| SCHEMBL7303313 | 0.75 | AGT (0.46) | AGTR1AGTR2AGT | |
| SCHEMBL7304989 | 0.75 | AGTR1 (0.48) | AGTR1AGTR2AGT | |
| SCHEMBL9203557 | 0.75 | AGTR1 (0.48) | AGTR1AGTR2AGT | |
| SCHEMBL7312371 | 0.75 | AGTR1 (0.46) | AGTR1AGTR2AGT | |
| SCHEMBL8861130 | 0.73 | AGTR1 (0.55) | AGTR1AGTR2AGTABCC3ABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076492-B2 | Process for preparing trityl olmesartan medoxomil and olmesartan medoxomil | CIPLA LIMITED (IN) | 2011-12-13 | — | — | US | disclosed |
| US-20100160643-A1 | Process for Preparing Trityl Olmesartan Medoxomil and Olmesartan Medoxomil | CIPLA LIMITED (IN) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160643-A1 | Process for Preparing Trityl Olmesartan Medoxomil and Olmesartan Medoxomil | MED1, AGTR1, MED12 | AGTR1 2/4885AGTR2 4/4885AGT 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.